Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer
Cancer Network,
The phase 3 XPORT-EC-042/ENGOT-EN20/GOG-3083 trial (NCT05611931) evaluating selinexor (Xpovio) as a maintenance-only therapy…
The phase 3 XPORT-EC-042/ENGOT-EN20/GOG-3083 trial (NCT05611931) evaluating selinexor (Xpovio) as a maintenance-only therapy…
Selinexor maintenance therapy did not significantly improve PFS vs placebo in TP53 wild-type advanced or recurrent endometrial…
Kathleen N. Moore, MD, discusses the need for individualized therapies, particularly for patients with nondeficient mismatch…